P1.13-29 Overall Response Rate of Nintedanib and Docetaxel in Combination With the Nutraceutical Use of Silibinin in Advanced NSCLC

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.886
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Focus on Nintedanib in NSCLC and Other Tumors

Frontiers in Medicine
Medicine
2016English

P1.13-11 PRO-CTCAE Toxicities in Advanced NSCLC Patients With EGFR Mutations: A Real World Assessment

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-44 CYFRA 21-1 as a Predictor to Response to Chemotherapy and Overall Survival in Patients With Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Afatinib in Advanced NSCLC: A Profile of Its Use

Drugs and Therapy Perspectives
Pharmacology
2018English

Role of KRAS-LCS6 Polymorphism in Advanced NSCLC Patients Treated With Erlotinib or Docetaxel in Second Line Treatment (TAILOR)

Scientific Reports
Multidisciplinary
2015English

P080 Efficacy and Safety of Docetaxel Plus Ramucirumab: A Consecutive Analysis of 68 Patients With Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Efficacy and Safety of Nintedanib in Patients With Advanced Idiopathic Pulmonary Fibrosis

BMC Pulmonary Medicine
PulmonaryRespiratory Medicine
2020English

P1.13-18 Exploring the Resistance Mechanism of Osimertinib and Monitoring the Treatment Response Using Plasma ctDNA in Chinese NSCLC Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA10.05 Effect of Early Steroids Use in Advanced NSCLC Patients Treated With Immunotherapy

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy